Brian Stover, MD - Research

Active clinical trials

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: 6 Months - 21 Years
Sexes: All

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: 1 Year - 25 Years
Sexes: All

My publications

4 publications

2025

Multi-Step Assembly of an RNA-Liposome Nanoparticle Formulation Revealed by Real-Time, Single-Particle Quantitative Imaging.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

鈥�

2019

Emerging trends in immunotherapy for pediatric sarcomas.

Journal of hematology & oncology

鈥�

2018

Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.

Nano letters

鈥�

2016

FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.

Histopathology

鈥�

BOB体育